ÂÜÀòÂÒÂ×

Steven Holtzman is a Co-Founder and board member of Shoreline Biosciences. He is the Chair of the boards of Qihan Biotech and Camp4 Biotherapeutics, both private biotechnology companies. Since January 2020, he has served as a Strategic Advisor to Decibel Therapeutics, where he served as the company’s first president and chief executive officer and a board member from 2016—2020. Prior to Decibel, from 2011 to 2016 he served as executive vice president, corporate development at Biogen, Inc., where he led eight new drug approvals. Previously, from 2001 to 2011, Steve was the founder, chief executive officer and board chair of Infinity Pharmaceuticals, Inc., a cancer drug discovery and development company. He was also, from 1994 to 2001, an early leader and the chief business officer of Millennium Pharmaceuticals, a pioneer in large-scale genetics and genomics. From 1986 to 1994 he was a co-founder, board member and executive vice president of DNX Corporation, the first transgenic animal company. He is a member of the board of directors of Molecular Partners, a member of the board of trustees of the Berklee College of Music, and a senior fellow at the Belfer Center for Science and International Affairs at the Harvard Kennedy School. He was appointed by President Clinton to the National Bioethics Advisory Commission and he also served as a member and vice chair of the board of the Hastings Center for the Life Sciences. He obtained his undergraduate degree in philosophy from Michigan State University and his graduate degree in philosophy from Oxford University, which he attended as a Rhodes Scholar.